Danaher Co. (NYSE:DHR) Shares Sold by Fosun International Ltd

Fosun International Ltd lowered its stake in shares of Danaher Co. (NYSE:DHR) by 34.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,200 shares of the conglomerate’s stock after selling 620 shares during the quarter. Fosun International Ltd’s holdings in Danaher were worth $278,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Wellington Management Group LLP increased its holdings in Danaher by 18.6% in the third quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock valued at $6,185,203,000 after buying an additional 3,905,449 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Danaher by 1.7% during the third quarter. Northern Trust Corp now owns 8,100,722 shares of the conglomerate’s stock worth $2,009,789,000 after purchasing an additional 134,905 shares during the last quarter. Flossbach Von Storch AG grew its holdings in shares of Danaher by 1.8% during the fourth quarter. Flossbach Von Storch AG now owns 4,601,351 shares of the conglomerate’s stock worth $1,064,477,000 after purchasing an additional 82,672 shares during the last quarter. Fisher Asset Management LLC grew its holdings in shares of Danaher by 6.2% during the fourth quarter. Fisher Asset Management LLC now owns 4,227,108 shares of the conglomerate’s stock worth $977,900,000 after purchasing an additional 248,140 shares during the last quarter. Finally, Invesco Ltd. grew its holdings in shares of Danaher by 13.2% during the third quarter. Invesco Ltd. now owns 4,070,455 shares of the conglomerate’s stock worth $1,009,880,000 after purchasing an additional 473,693 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Danaher stock remained flat at $249.55 during mid-day trading on Thursday. 141,736 shares of the company’s stock were exchanged, compared to its average volume of 2,700,865. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $259.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51. The company has a market cap of $184.84 billion, a P/E ratio of 42.30, a P/E/G ratio of 3.82 and a beta of 0.83. The business’s 50-day simple moving average is $248.27 and its 200-day simple moving average is $233.19.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. During the same period last year, the company posted $2.36 earnings per share. The firm’s quarterly revenue was down 2.6% compared to the same quarter last year. On average, equities analysts forecast that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be paid a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.43%. Danaher’s payout ratio is currently 18.31%.

Insiders Place Their Bets

In other Danaher news, Director Alan G. Spoon sold 708 shares of Danaher stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the sale, the director now directly owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, SVP Georgeann Couchara sold 2,622 shares of the business’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total value of $636,280.74. Following the completion of the sale, the senior vice president now owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Alan G. Spoon sold 708 shares of the business’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the sale, the director now directly owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The disclosure for this sale can be found here. In the last three months, insiders sold 103,984 shares of company stock valued at $25,997,094. Company insiders own 10.90% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Citigroup raised their price objective on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Barclays increased their target price on shares of Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 24th. KeyCorp increased their target price on shares of Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. Robert W. Baird increased their target price on shares of Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 24th. Finally, Bank of America increased their target price on shares of Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 24th. Six analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $267.31.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.